Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands
    5.
    发明申请
    Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands 审中-公开
    咪唑并吡嗪,咪唑并吡啶和咪唑并嘧啶作为Crf1受体配体

    公开(公告)号:US20080015196A1

    公开(公告)日:2008-01-17

    申请号:US11578254

    申请日:2005-04-15

    CPC分类号: C07D487/04 C07D471/04

    摘要: Novel aryl substituted imidazopyrazines, imidazopyrimidines, and imidazopyridines are provided. Such compounds can act as selective modulators of CRF receptors. The imidazopyrazines, imidazopyrimidines, and imidazopyridines compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds provided are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

    摘要翻译: 提供了新的芳基取代的咪唑并吡嗪,咪唑并嘧啶和咪唑并吡啶。 这些化合物可以作为CRF受体的选择性调节剂。 本文提供的咪唑并吡嗪,咪唑并嘧啶和咪唑并吡啶化合物可用于治疗许多CNS和周围疾病,特别是压力,焦虑,抑郁,心血管疾病和进食障碍。 还提供了治疗这种疾病以及包装的药物组合物的方法。 提供的化合物也可用作CRF受体定位的探针,并且作为用于CRF受体结合的测定中的标准物。 给出了在受体定位研究中使用化合物的方法。